Newhedge.io, a Bitcoin analytics platform focused on on-chain market intelligence, today announced the launch of the Newhedge API, providing developers, institutions, and analysts with direct ...

A new collaboration between EMBL's European Bioinformatics Institute (EMBL-EBI), Google DeepMind, NVIDIA, and Seoul National University has made millions of AI-predicted protein complex structures ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.

Integrating AI into chip workflows is pushing companies to overhaul their data management strategies, shifting from passive storage to active, structured, and machine-readable systems. As training and ...

Founded by veterans of Mosaic, Ezra is using AI and capital networks to modernize financing for real-world assets SAN ...

As more and more Americans turn to generative AI tools to answer their questions, federal officials are working to ensure that third-party chatbots can more easily rely on public data to inform ...

Abstract: Accurate global digital elevation models (GDEMs) are essential for various geoscience applications. However, the accuracy of GDEMs in vegetated mountainous regions is relatively low due to ...

Research analyzing 4,700 leading websites reveals that 64% of third-party applications now access sensitive data without business justification, up from 51% in 2024. Government sector malicious ...

Are you among those who receive the frustrating error message “You must start Microsoft Access by double-clicking a Microsoft Access file” when trying to open the ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...